294 related articles for article (PubMed ID: 7932147)
1. Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Part 1: Systemic administration.
Giovanni A; Sieber BA; Heikkila RE; Sonsalla PK
J Pharmacol Exp Ther; 1994 Sep; 270(3):1000-7. PubMed ID: 7932147
[TBL] [Abstract][Full Text] [Related]
2. Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Part 2: Central administration of 1-methyl-4-phenylpyridinium.
Giovanni A; Sonsalla PK; Heikkila RE
J Pharmacol Exp Ther; 1994 Sep; 270(3):1008-14. PubMed ID: 7932148
[TBL] [Abstract][Full Text] [Related]
3. Correlation between the neostriatal content of the 1-methyl-4-phenylpyridinium species and dopaminergic neurotoxicity following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration to several strains of mice.
Giovanni A; Sieber BA; Heikkila RE; Sonsalla PK
J Pharmacol Exp Ther; 1991 May; 257(2):691-7. PubMed ID: 2033514
[TBL] [Abstract][Full Text] [Related]
4. In vitro studies of striatal vesicles containing the vesicular monoamine transporter (VMAT2): rat versus mouse differences in sequestration of 1-methyl-4-phenylpyridinium.
Staal RG; Hogan KA; Liang CL; German DC; Sonsalla PK
J Pharmacol Exp Ther; 2000 May; 293(2):329-35. PubMed ID: 10772999
[TBL] [Abstract][Full Text] [Related]
5. D-deprenyl protects nigrostriatal neurons against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurotoxicity.
Muralikrishnan D; Samantaray S; Mohanakumar KP
Synapse; 2003 Oct; 50(1):7-13. PubMed ID: 12872288
[TBL] [Abstract][Full Text] [Related]
6. In brown Norway rats, MPP+ is accumulated in the nigrostriatal dopaminergic terminals but it is not neurotoxic: a model of natural resistance to MPTP toxicity.
Zuddas A; Fascetti F; Corsini GU; Piccardi MP
Exp Neurol; 1994 May; 127(1):54-61. PubMed ID: 8200437
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of brain vesicular monoamine transporter (VMAT2) enhances 1-methyl-4-phenylpyridinium neurotoxicity in vivo in rat striata.
Staal RG; Sonsalla PK
J Pharmacol Exp Ther; 2000 May; 293(2):336-42. PubMed ID: 10773000
[TBL] [Abstract][Full Text] [Related]
8. A model of chronic neurotoxicity: long-term retention of the neurotoxin 1-methyl-4-phenylpyridinium (MPP+) within catecholaminergic neurons.
Johannessen JN
Neurotoxicology; 1991; 12(2):285-302. PubMed ID: 1956587
[TBL] [Abstract][Full Text] [Related]
9. CEP-1347/KT-7515, an inhibitor of c-jun N-terminal kinase activation, attenuates the 1-methyl-4-phenyl tetrahydropyridine-mediated loss of nigrostriatal dopaminergic neurons In vivo.
Saporito MS; Brown EM; Miller MS; Carswell S
J Pharmacol Exp Ther; 1999 Feb; 288(2):421-7. PubMed ID: 9918541
[TBL] [Abstract][Full Text] [Related]
10. Regional biotransformation of MPTP in the CNS of rodents and its relation to neurotoxicity.
Nwanze E; Souverbie F; Jonsson G; Sundström E
Neurotoxicology; 1995; 16(3):469-77. PubMed ID: 8584278
[TBL] [Abstract][Full Text] [Related]
11. MPTP-induced oxidative stress and neurotoxicity are age-dependent: evidence from measures of reactive oxygen species and striatal dopamine levels.
Ali SF; David SN; Newport GD; Cadet JL; Slikker W
Synapse; 1994 Sep; 18(1):27-34. PubMed ID: 7825121
[TBL] [Abstract][Full Text] [Related]
12. Neurotoxicity studies with the monoamine oxidase B substrate 1-methyl-3-phenyl-3-pyrroline.
Ogunrombi MO; Malan SF; Terre'Blanche G; Castagnoli K; Castagnoli N; Bergh JJ; Petzer JP
Life Sci; 2007 Jul; 81(6):458-67. PubMed ID: 17655878
[TBL] [Abstract][Full Text] [Related]
13. Effects of noradrenergic lesions on MPTP/MPP+ kinetics and MPTP-induced nigrostriatal dopamine depletions.
Fornai F; Alessandrì MG; Torracca MT; Bassi L; Corsini GU
J Pharmacol Exp Ther; 1997 Oct; 283(1):100-7. PubMed ID: 9336313
[TBL] [Abstract][Full Text] [Related]
14. Attenuation by dopamine uptake blockers of the inhibitory effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and some of its analogs on NADH-linked metabolism in mouse neostriatal slices.
Ofori S; Heikkila RE; Nicklas WJ
J Pharmacol Exp Ther; 1989 Oct; 251(1):258-66. PubMed ID: 2571719
[TBL] [Abstract][Full Text] [Related]
15. Lack of involvement of glutamate-induced excitotoxicity in MPP+ toxicity in striatal dopaminergic terminals: possible involvement of ascorbate.
Matarredona ER; Santiago M; Machado A; Cano J
Br J Pharmacol; 1997 Jul; 121(5):1038-44. PubMed ID: 9222565
[TBL] [Abstract][Full Text] [Related]
16. Fucoidan protects against dopaminergic neuron death in vivo and in vitro.
Luo D; Zhang Q; Wang H; Cui Y; Sun Z; Yang J; Zheng Y; Jia J; Yu F; Wang X; Wang X
Eur J Pharmacol; 2009 Sep; 617(1-3):33-40. PubMed ID: 19545563
[TBL] [Abstract][Full Text] [Related]
17. Methamphetamine- and 1-methyl-4-phenyl- 1,2,3, 6-tetrahydropyridine-induced dopaminergic neurotoxicity in inducible nitric oxide synthase-deficient mice.
Itzhak Y; Martin JL; Ali SF
Synapse; 1999 Dec; 34(4):305-12. PubMed ID: 10529724
[TBL] [Abstract][Full Text] [Related]
18. Effects of testosterone upon MPTP-induced neurotoxicity of the nigrostriatal dopaminergic system of C57/B1 mice.
Dluzen DE
Brain Res; 1996 Apr; 715(1-2):113-8. PubMed ID: 8739629
[TBL] [Abstract][Full Text] [Related]
19. [Study of extracellular concentration of dopamine and its metabolites in mice striatum by a microdialysis technique at intraperitoneal administration of MPTP].
Averkin RG; Korshunov VA; Shchegolevskiĭ NV; Mats VN; Markevich VA; Grigor'ian GA; Bazian AS
Zh Vyssh Nerv Deiat Im I P Pavlova; 2010; 60(1):109-19. PubMed ID: 20352690
[TBL] [Abstract][Full Text] [Related]
20. Differences in the disposition and toxicity of 1-methyl-4-phenylpyridinium in cultured rat and mouse astrocytes.
Tsai MJ; Lee EH
Glia; 1994 Dec; 12(4):329-35. PubMed ID: 7890335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
